Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics
- Emerging Trends
- Analysis by Segment
- Analysis by Region
- Conclusion
Chapter 2 Market Overview
- Mental Health Disorders Overview
- Analysis of Macroeconomic Factors
- Government Funding and Public Healthcare Budgets
- Labor Market Dynamics
- Impact of U.S. Tariffs
- Porter's Five Forces Analysis
- Bargaining Power of Buyers: High
- Bargaining Power of Suppliers: Low to Moderate
- Threat of New Entrants: Moderate
- Threat of Substitutes: Moderate
- Industry Rivalry: High
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Widespread Global Prevalence of Mental Health Disorders
- Rising Awareness and Declining Stigma Driving Improved Diagnosis of Mental Health Disorders
- Advances in Drug Development and Novel Mechanisms of Action
- Expansion of Healthcare Access and Insurance Coverage
- Market Restraints
- Low Treatment Penetration Despite High Disease Burden
- Poor Treatment Adherence and High Discontinuation Rates
- Drug Shortages
- Market Opportunities
- Shift Toward Long-Acting and Extended -Release Therapies
- Growing Focus on Treatment-Resistant Mental Health Conditions
- Integration of Digital Therapeutics with Pharmacotherapy
Chapter 4 Regulatory Landscape
- Overview
- U.S.
- Key Federal Actors and their Roles
- Europe
- Japan
Chapter 5 Emerging Technologies and Developments
- Emerging Technologies and Developments
- Psychedelics
- Neuroplastogens
- Neurosteroids (GABA-A Positive Allosteric Modulators)
- Clinical Trial Analysis
- By Condition Type
- Therapeutic Candidates in Late-Stage Clinical Trials
Chapter 6 Market Segmentation Analysis
- Segmental Breakdown
- Global Market for Prescription Drugs to Treat Mental Health Disorders, by Disorder Type
- Depression and Anxiety Disorders
- Selective Serotonin Reuptake Inhibitors
- Atypical Antidepressants
- Others
- Market Revenue and Forecast
- Attention Deficit Hyperactivity Disorder
- Stimulants
- Non-stimulant
- Market Revenue and Forecast
- Schizophrenia
- Antipsychotics
- Emerging Drug Classes
- Market Revenue and Forecast
- Substance Use Disorders
- Buprenorphine
- Varenicline
- Naltrexone
- Others
- Market Revenue and Forecast
- Geographic Breakdown
- Global Market for Prescription Drugs to Treat Mental Health Disorders, by Region
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
List of Tables
Summary Table: Global Market for Prescription Drugs to Treat Mental Health Disorders, by Region, Through 2031
Table 1: Therapeutic Candidates in Phase 3 for Major Depressive Disorder (MDD) and Anxiety Disorder
Table 2: Therapeutic Candidates in Phase 2 or 3 for Substance Use Disorders (SUD)
Table 3: Therapeutic Candidates in Phase 3 for Schizophrenia
Table 4: Therapeutic Candidates in Phase 3 for Attention-Deficit/Hyperactivity Disorder
Table 5: Global Market for Prescription Drugs to Treat Mental Health Disorders, by Disorder Type, Through 2031
Table 6: Key Actively Marketed Branded Depression Drugs
Table 7: Global Market for Prescription Drugs to Treat Depression and Anxiety Disorders, by Drug Type, Through 2031
Table 8: ADHD Rates, by Country, 2023
Table 9: Types of Stimulant Drugs Based on Response Time and Duration of Action
Table 10: FDA-Approved Medications for ADHD
Table 11: Global Market for Prescription Drugs to Treat Attention-Deficit/Hyperactivity Disorder, by Drug Type, Through 2031
Table 12: Global Market for Prescription Drugs to Treat Schizophrenia, Through 2031
Table 13: Ten Drug Classes Commonly Associated with Substance-Related Disorders
Table 14: The Substance Use Disorder Treatment Gap in the U.S., 2024
Table 15: FDA-Approved Buprenorphine Medications for Opioid Use Disorder (MOUD)
Table 16: Global Market for Prescription Drugs to Treat Substance Use Disorders, by Drug Type, Through 2031
Table 17: Global Market for Prescription Drugs to Treat Mental Health Disorders, by Region, Through 2031
Table 18: North American Market for Prescription Drugs to Treat Mental Health Disorders, by Disorder Type, Through 2031
Table 19: North American Market for Prescription Drugs to Treat Mental Health Disorders, by Country, Through 2031
Table 20: Depressive Disorder in Selected European Countries, 2023
Table 21: European Market for Prescription Drugs to Treat Mental Health Disorders,by Disorder Type, Through 2031
Table 22: European Market for Prescription Drugs to Treat Mental Health Disorders,by Country, Through 2031
Table 23: Depressive Disorder in Selected Asia-Pacific Countries, 2023
Table 24: Asia-Pacific Market for Prescription Drugs to Treat Mental Health Disorders, by Disorder Type, Through 2031
Table 25: Asia-Pacific Market for Prescription Drugs to Treat Mental Health Disorders, by Country, Through 2031
Table 26: Prevalence of Mental Disorders in Asia-Pacific, 2023
Table 27: Depressive Disorder in Selected Middle East and Africa Countries, 2023
Table 28: Middle East and Africa Market for Prescription Drugs to Treat Mental Health Disorders, by Disorder Type, Through 2031
Table 29: Depressive Disorder in Selected South America Countries, 2023
Table 30: South American Market for Prescription Drugs to Treat Mental Health Disorders, by Disorder Type, Through 2031
Table 31: Information Sources for this Report
Table 32: Abbreviations Used in This Report
Table 33: AbbVie Inc.: Company Snapshot
Table 34: AbbVie Inc.: Financial Performance, FY 2024 and 2025
Table 35: AbbVie Inc.: Product Portfolio
Table 36: AbbVie Inc.: News/Key Developments, 2024-2025
Table 37: Alkermes: Company Snapshot
Table 38: Alkermes: Financial Performance, FY 2024 and 2025
Table 39: Alkermes: Product Portfolio
Table 40: Axsome Therapeutics Inc.: Company Snapshot
Table 41: Axsome Therapeutics Inc.: Financial Performance, FY 2024 and 2025
Table 42: Axsome Therapeutics Inc.: Product Portfolio
Table 43: Braeburn Inc.: Company Snapshot
Table 44: Braeburn Inc.: Product Portfolio
Table 45: Camurus AB: Company Snapshot
Table 46: Camurus AB: Financial Performance, FY 2024 and 2025
Table 47: Camurus AB: Product Portfolio
Table 48: Camurus AB: News/Key Developments, 2025
Table 49: Collegium Pharmaceutical: Company Snapshot
Table 50: Collegium Pharmaceutical: Financial Performance, FY 2024 and 2025
Table 51: Collegium Pharmaceutical: Product Portfolio
Table 52: Collegium Pharmaceutical: News/Key Developments, 2024
Table 53: Corium LLC.: Company Snapshot
Table 54: Corium LLC.: Product Portfolio
Table 55: H. Lundbeck A/S: Company Snapshot
Table 56: H. Lundbeck A/S: Financial Performance, FY 2024 and 2025
Table 57: H. Lundbeck A/S: Product Portfolio
Table 58: H. Lundbeck A/S: News/Key Developments, 2024-2025
Table 59: Indivior Pharmaceuticals Inc: Company Snapshot
Table 60: Indivior Pharmaceuticals Inc: Financial Performance, FY 2024 and 2025
Table 61: Indivior Pharmaceuticals Inc: Product Portfolio
Table 62: Indivior Pharmaceuticals Inc: News/Key Developments, 2025
Table 63: Johnson & Johnson: Company Snapshot
Table 64: Johnson & Johnson: Financial Performance, FY 2024 and 2025
Table 65: Johnson & Johnson: Product Portfolio
Table 66: Johnson & Johnson: News/Key Developments, 2025
Table 67: Otsuka Pharmaceutical Co. Ltd.: Company Snapshot
Table 68: Otsuka Pharmaceutical Co. Ltd.: Product Portfolio
Table 69: Otsuka Pharmaceutical Co. Ltd.: News/Key Developments, 2025-2026
Table 70: Supernus Pharmaceuticals: Company Snapshot
Table 71: Supernus Pharmaceuticals: Financial Performance, FY 2024 and 2025
Table 72: Supernus Pharmaceuticals: Product Portfolio
Table 73: Supernus Pharmaceuticals: News/Key Developments, 2025
Table 74: Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 75: Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 76: Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 77: Tris Pharma Inc.: Company Snapshot
Table 78: Tris Pharma Inc.: Product Portfolio
Table 79: Viatris Inc.: Company Snapshot
Table 80: Viatris Inc.: Financial Performance, FY 2024 and 2025
Table 81: Viatris Inc.: Product Portfolio
Table 82: Viatris Inc.: News/Key Developments, 2026
Table 83: Emerging Startups/Market Disruptors
List of Figures
Summary Figure: Global Market Shares of Prescription Drugs to Treat Mental Health Disorders, by Region, 2025
Figure 1: Porter’s Five Forces Analysis- Mental Health Disorders Pharmacotherapy Industry
Figure 2: Market Dynamics of Pharmaceutical Treatments for Mental Health Disorders
Figure 3: Global Mental Health Disorders Prevalence, 2023
Figure 4: Active Pharmacotherapy Clinical Trials of Mental Health Disorders, by Condition, 2026
Figure 5: Global Market Shares of Prescription Drugs to Treat Mental Health Disorders, by Disorder Type, 2025
Figure 6: Global Market Shares of Prescription Drugs to Treat Depression and Anxiety Disorders, by Drug Type, 2025
Figure 7: Global Market Shares of Prescription Drugs to Treat Attention-Deficit/Hyperactivity Disorder, by Drug Type, 2025
Figure 8: Global Market Shares of Prescription Drugs to Treat Substance Use Disorders, by Drug Type, 2025
Figure 9: Global Market Shares of Prescription Drugs to Treat Mental Health Disorders, by Region, 2025
Figure 10: North American Market Shares of Prescription Drugs to Treat Mental Health Disorders, by Disorder Type, 2025
Figure 11: North American Market Shares of Prescription Drugs to Treat Mental Disorders, by Country, 2025
Figure 12: European Market Shares of Prescription Drugs to Treat Mental Health Disorders, by Disorder Type, 2025
Figure 13: European Market Shares of Prescription Drugs to Treat Mental Health Disorders, by Country, 2025
Figure 14: Asia-Pacific Market Shares of Prescription Drugs to Treat Mental Health Disorders, by Disorder Type, 2025
Figure 15: Asia-Pacific Market Shares of Prescription Drugs to Treat Mental Health Disorders, by Country, 2025
Figure 16: Middle East and Africa Market Shares of Prescription Drugs to Treat Mental Health Disorders, by Disorder Type, 2025
Figure 17: South American Market Shares of Prescription Drugs to Treat Mental Health Disorders, by Disorder Type, 2025
Figure 18: Global Market Shares of Mental Health Disorders Drugs, by Company, 2025
Figure 19: AbbVie Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 20: AbbVie Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 21: ALKERMES: Revenue Shares, by Business Unit, FY 2025
Figure 22: ALKERMES: Revenue Shares, by Country/Region, FY 2025
Figure 23: Axsome Therapeutics Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 24: Axsome Therapeutics Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 25: Camurus AB: Revenue Shares, by Business Unit, FY 2025
Figure 26: Camurus AB: Revenue Shares, by Country/Region, FY 2025
Figure 27: Collegium Pharmaceutical: Revenue Shares, by Business Unit, FY 2025
Figure 28: H. Lundbeck A/S: Revenue Shares, by Business Unit, FY 2025
Figure 29: H. Lundbeck A/S: Revenue Shares, by Country/Region, FY 2025
Figure 30: Indivior Pharmaceuticals Inc: Revenue Shares, by Business Unit, FY 2025
Figure 31: Indivior Pharmaceuticals Inc: Revenue Shares, by Country/Region, FY 2025
Figure 32: Johnson & Johnson: Revenue Shares, by Business Unit, FY 2025
Figure 33: Johnson & Johnson: Revenue Shares, by Country/Region, FY 2025
Figure 34: Supernus Pharmaceuticals: Revenue Shares, by Business Unit, FY 2025
Figure 35: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 36: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 37: Viatris Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 38: Viatris Inc.: Revenue Shares, by Country/Region, FY 2025
